New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case

Q: What does this research mean for the field?

Calcitonin gene-related peptide (CGRP) inhibitor therapy can be associated with the development of new-onset alopecia areata. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Luca Valtellini; Mauro Barbareschi; Silvia Mariel Ferrucci; Angelo Valerio Marzano; Andrea Sechi

doi:10.4081/dr.2026.10802

August 24, 2026Dermatology ReportsOpen Access

New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case

View Full Paper

Ask AI

Bookmark

Share

Key Points

Document the first known occurrence of new-onset alopecia areata arising during treatment with calcitonin gene-related peptide (CGRP) inhibitors.
Clinical case evaluation of a patient presenting with new-onset patchy hair loss following calcitonin gene-related peptide (CGRP) inhibitor therapy for migraine.
Identifies new-onset alopecia areata as an undescribed adverse manifestation linked to CGRP inhibitor therapy.
Contrasts autoimmune alopecia areata against previously reported drug-induced telogen effluvium rates ranging from 1.10% to 7.23% in patients receiving CGRP antagonists.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Case report reveals new-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy, suggesting a potential novel adverse autoimmune response to migraine prophylaxis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Valtellini et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe96710c91c1e9262104b https://doi.org/10.4081/dr.2026.10802

View Full Paper

Ask AI

Bookmark

Share

New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case

Key Points

No abstract yet

Implication

Discussion

Cite This Study

New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Dermatology Reports

Keep reading

More related papers

More from Dermatology Reports